Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report
Management of paraneoplastic membranous nephropathy (MN) is directed toward the underlying malignancy, and prescriptions of immune checkpoint inhibitors (ICIs) are skyrocketing in the field of oncology. However, this drug category is usually discouraged for patients with autoimmune disorders (AIDs)...
Saved in:
| Main Authors: | Rayane Benyahia, Magali Colombat, Serigne Gueye, Julien Mazières, Julie Belliere |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Kidney Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059525000032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review
by: Huan Wang, et al.
Published: (2024-12-01) -
Pembrolizumab: The nut cracker
by: Gangothri Selvarajan
Published: (2020-01-01) -
Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report
by: Zaid Khamis, et al.
Published: (2025-08-01) -
Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature
by: Kazuaki Harada, et al.
Published: (2020-05-01) -
The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
by: Shun Li, et al.
Published: (2025-04-01)